• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SD filed by Waters Corporation

    5/30/25 4:30:42 PM ET
    $WAT
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $WAT alert in real time by email
    SD 1 d57342dsd.htm SD SD
     
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

    FORM SD

     

     

    Specialized Disclosure Report

     

     

    Waters Corporation

    (Exact name of registrant as specified in its charter)

     

     

     

    Delaware

      001-14010   13-3668640
    (State or other jurisdiction of   (Commission   (I.R.S. Employer
    incorporation)   file number)   Identification No.)
    34 Maple Street, Milford, Massachusetts     01757
    (Address of principal executive offices)     (Zip code)

    Keeley A. Aleman

    508-478-2000

    (Name and telephone number, including area code, of the person to contact in connection with this report.)

     

     

    Check the appropriate box to indicate the rule pursuant to which this form is being filed:

     

    ☒

    Rule 13p-1 under the Securities Exchange Act (17 CFR 240.13p-1) for the reporting period from January 1 to December 31, 2024.

     

    ☐

    Rule 13q-1 under the Securities Exchange Act (17 CFR 240.13q-1) for the fiscal year ended.

     

     
     


    Section 1 - Conflict Minerals Disclosure

    Item 1.01 Conflict Minerals Disclosure

    This filing is being made by Waters Corporation (“Waters”, the “Company”, “we”, “us”, or “our”) for the calendar year January 1 to December 31, 2024, in accordance with Rule 13p-1 (“Rule 13p-1”) under the Securities Exchange Act of 1934 (the “1934 Act”) and Form SD (collectively, the “Conflict Minerals Rule”). Consistent with the Conflict Minerals Rule, as used herein, “Conflict Minerals” or “3TG” are tin (cassiterite), tungsten (wolframite), tantalum (columbite-tantalite or coltan) and gold. In accordance with the Updated Statement on the Effect of the Court of Appeals Decision on the Conflict Minerals Rule issued by the Division of Corporation Finance of the Securities and Exchange Commission on April 7, 2017, we have not included a Conflict Minerals Report exhibit as part of this filing.

    Company Overview

    Waters is a specialty measurement company that operates with a fundamental purpose to advance the science that enables our customers to enhance human health and well-being. The Company has pioneered analytical workflow solutions involving liquid chromatography, mass spectrometry, thermal analysis and light scattering innovations serving the life, materials, and food sciences.

     

      •  

    Waters sells and services high performance liquid chromatography, ultraperformance liquid chromatography and mass spectrometry technology systems and support products, including chromatography columns, other consumable products, and comprehensive post-warranty service plans. These systems are complementary products that are frequently employed together and sold as integrated instrument systems using common software platforms.

     

      •  

    Waters is also a developer and supplier of advanced software-based products that interface with the Company’s instruments, as well as other manufacturers’ instruments.

     

      •  

    Through its TA Instruments product line, the Company designs, manufactures, sells, and services thermal analysis, rheology and calorimetry instruments.

     

      •  

    Through Wyatt Technology (a business acquired by Waters in May 2023), Waters researches, develops and commercializes light scattering instruments used in the pharmaceutical, and biotechnology academic institutions.

    Product Scoping; Reasonable Country of Origin Inquiry (“RCOI”)

    The Company determined that 3TG are used in certain components contained in the Company’s instrument systems, which are products that the Company manufactures. These 3TG are necessary to the functionality or production of the Company’s instrument systems.

    As required by the Conflict Minerals Rule, the Company conducted a RCOI to determine whether any of the 3TG in the Company’s products originate in the Democratic Republic of the Congo (the “DRC”) or its adjoining countries or are from recycled or scrap sources. The Company’s due diligence program is based upon industry guidance published by the Organisation for Economic Co-operation and Development, the Due Diligence Guidance for Responsible Supply Chains of Minerals from Conflict-Affected and High-Risk Areas (the “OECD Guidance”).

    As part of our RCOI, we asked 6,380 potentially in-scope suppliers to complete the Conflict Minerals Reporting Template (“CMRT”), developed by the Responsible Minerals Initiative (the “RMI”). The CMRT includes questions about suppliers’ uses and sourcing of 3TG, as well as questions about their own due diligence measures. All potentially in-scope suppliers received a letter from the Company’s Senior Vice President of Global Operations, requesting their compliance with the annual RCOI process.

    Due Diligence Program

    The Company has designed its due diligence program to align with ongoing compliance with the Conflict Minerals Rule. As recommended by the OECD Guidance, the Company published a Conflict Minerals Statement, which is made available to employees, suppliers and the public on our website at https://www.waters.com/nextgen/us/en/about-waters/corporate-governance/conflict-minerals-statement.html. Among other things, the Company’s due diligence program includes the review of its worldwide supply chain for materials that contain 3TG and the evaluation of the risk that these materials are from sources that directly or indirectly finance or benefit armed groups in the DRC or an adjoining country.

    The Company’s program has several elements including, but not limited to, the following:

     

      •  

    Establishing a cross-functional team with representation from Product Stewardship, Trade Compliance, Procurement, Sustainability, Legal, Finance, and Investor Relations to monitor supply chain due diligence and reporting. Waters has permanent staff dedicated to the management of this program.

     

      •  

    Having a Supplier Environmental and Social Responsibility (ESR) Code of Conduct. Pursuant to the ESR Code of Conduct, the Company expects its suppliers to exercise due diligence on their own supply chains and to make their due diligence findings available to the Company. The ESR Code of Conduct indicates that the Company reserves the right to take remedial action up to and including termination in the event of supplier non-compliance.


      •  

    Including language in the Company’s purchase order terms and conditions related to Conflict Minerals reporting and compliance.

     

      •  

    Holding periodic virtual training with certain critical suppliers about our Conflict Minerals compliance program, our reporting obligations, and the importance of supplier participation.

     

      •  

    Engaging with a third-party vendor to administer the supplier survey, to tabulate survey results, and to help measure year-over-year performance.

     

      •  

    Utilizing our [email protected] email as a mechanism for our suppliers and other third parties to report compliance questions or issues to the Company.

     

      •  

    Notifying the Company’s Procurement organization about suppliers who do not respond to the RCOI.

     

      •  

    In certain circumstances where a supplier acknowledges the use of smelters not certified by the RMI, removing the supplier from the Company’s approved vendor list.

    Findings and Results

    For the calendar year ended December 31, 2024, the number of our total in-scope suppliers increased from 5,722 to 6,380. This increase is due to the net addition of suppliers in the ordinary course of business. Our methodology is intended to increase visibility into our products and their components, including those components we consider to be at lower risk of containing 3TG. The Company received responses from approximately 75% of the 6,380 potentially in-scope suppliers contacted, and the responses received were applicable to 84.2% of the 96,832 parts from those suppliers.

     

      •  

    Some suppliers indicated that the products, components, and materials they sold the Company contained no 3TG, or that they only source 3TG from smelters and refiners that conformed with the RMI’s Responsible Minerals Assurance Process assessment.

     

      •  

    Some suppliers indicated that they could not determine which smelters or refiners produced the 3TG used in the products, components and materials sold to the Company or could not determine the county of origin of the 3TG used in their products.

     

      •  

    No suppliers informed the Company, in response to the Company’s RCOI survey, that they obtained 3TG from mines controlled by armed groups in the DRC or an adjoining country.

    As a result of the information the Company received from its suppliers for the calendar year ended December 31, 2024, the Company was not able to determine with certainty the country of origin of the 3TG in our products. However, the Company does not have reason to believe that any 3TG used in its products originated from mines controlled by an armed group in the DRC or an adjoining country.

    Future Due Diligence Considerations

    The Company is committed to continuing to evolve our RCOI and due diligence program. The Company intends to work to improve survey response rates from its suppliers over time. The Company also intends to continue to update our RCOI and due diligence program processes and procedures as appropriate.

    The Company’s Form SD is publicly available on our website at https://ir.waters.com/financials/sec-filings. Links to websites included in this Form SD are provided solely for information and convenience. The content on any websites named, hyperlinked, or otherwise referenced herein, including the content of any reports that are noted as being posted on our website, is not, and shall not be deemed to be, incorporated by reference into this Form SD or into any of our other filings with the Securities and Exchange Commission.

    Section 2 - Resource Extraction Issuer Disclosure

     

    Item 2.01

    Resource Extraction Issuer Disclosure and Report

    Not applicable.

    Section 3 - Exhibits

     

    Item 3.01

    Exhibits

    Not applicable.


    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the duly authorized undersigned.

     

        WATERS CORPORATION
    Dated: May 30, 2025     By:  

    /s/ Christos Ross

        Name:   Christos Ross
        Title:   Senior Vice President, Global Operations
    Get the next $WAT alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $WAT

    DatePrice TargetRatingAnalyst
    3/31/2025$460.00Sector Weight → Overweight
    KeyBanc Capital Markets
    3/26/2025$396.00 → $407.00Neutral → Outperform
    Robert W. Baird
    2/13/2025$450.00Sector Perform → Sector Outperform
    Scotiabank
    2/10/2025$360.00 → $415.00Underweight → Equal Weight
    Barclays
    1/10/2025$430.00Mkt Perform → Outperform
    Bernstein
    12/23/2024Sector Perform
    Scotiabank
    10/8/2024$355.00 → $415.00Hold → Buy
    Jefferies
    8/28/2024$380.00Overweight
    Wells Fargo
    More analyst ratings

    $WAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Waters upgraded by KeyBanc Capital Markets with a new price target

      KeyBanc Capital Markets upgraded Waters from Sector Weight to Overweight and set a new price target of $460.00

      3/31/25 7:57:55 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Robert W. Baird with a new price target

      Robert W. Baird upgraded Waters from Neutral to Outperform and set a new price target of $407.00 from $396.00 previously

      3/26/25 7:47:54 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters upgraded by Scotiabank with a new price target

      Scotiabank upgraded Waters from Sector Perform to Sector Outperform and set a new price target of $450.00

      2/13/25 8:14:37 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Financials

    Live finance-specific insights

    See more
    • Waters Corporation (NYSE: WAT) Reports First Quarter 2025 Financial Results

      Highlights Strong start to the year as first quarter 2025 sales of $662 million landed at the high-end of guidance range; grew 4% as reported and 7% in constant currencyResults led by instrument growth of 11% in constant currency, driven by strong momentum in Pharma and Industrial end marketsEarnings landed at the high-end of guidance range with GAAP EPS of $2.03 and non-GAAP EPS of $2.25Raising full-year constant currency sales growth guidance to +5.0% to +7.0%, given first quarter strengthRaising full-year non-GAAP EPS guidance to the range of $12.75 to $13.05, net of tariff impact, operational actions, and improvement in FXFirst Quarter 2025 MILFORD, Mass., May 6, 2025 /PRNewswire/ -- Wat

      5/6/25 6:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • STAAR Surgical Announces Changes to Board of Directors

      STAAR Surgical Company (NASDAQ:STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today announced changes to its Board of Directors. The Company announced that the Board appointed Louis E. Silverman, who served on the Company's Board from 2014-2022, as a director, effective April 24, 2025. The Company also announced that Aimee S. Weisner, who has served as a director since 2022, has chosen not to stand for re-election to the Board when her term expires at the Company's 2025 annual meeting of shareholders in June. In addition, the Company announced that Wei Jiang, who has served as a director since 2024, has agreed to

      4/24/25 5:00:00 PM ET
      $AZN
      $CRVL
      $LLY
      $MDRX
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Specialty Insurers
      Finance
    • Waters Corporation Schedules First Quarter 2025 Earnings Conference Call

      MILFORD, Mass., April 8, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) will hold its Q1 2025 financial results conference call on Tuesday, May 6th, 2025 at 8:00 a.m. Eastern Time. A live webcast of the presentation will be available on Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will also be available until at least June 3rd, 2025, at midnight Eastern Time. About Waters Corporation  Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences for over 65 years. Our Company helps ensure the efficacy of medicines, the safety of food

      4/8/25 4:30:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Waters Corporation

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      11/12/24 11:54:03 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/14/24 9:37:22 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form SC 13G/A filed by Waters Corporation (Amendment)

      SC 13G/A - WATERS CORP /DE/ (0001000697) (Subject)

      2/13/24 5:17:31 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Fearon Richard H bought $332,900 worth of shares (1,000 units at $332.90), increasing direct ownership by 153% to 1,653 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/29/24 11:23:35 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    SEC Filings

    See more
    • SEC Form SD filed by Waters Corporation

      SD - WATERS CORP /DE/ (0001000697) (Filer)

      5/30/25 4:30:42 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation

      8-K - WATERS CORP /DE/ (0001000697) (Filer)

      5/29/25 4:15:21 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form 8-K filed by Waters Corporation

      8-K - WATERS CORP /DE/ (0001000697) (Filer)

      5/23/25 4:30:52 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Leadership Updates

    Live Leadership Updates

    See more

    $WAT
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

      MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

      5/21/25 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Heather Knight to Board of Directors

      MILFORD, Mass., Aug. 14, 2024 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the appointment of Heather Knight to its Board of Directors effective August 14, 2024. Ms. Knight currently serves as Executive Vice President and Group President, Medical Products and Therapies at Baxter International. Heather is an accomplished leader who brings decades of experience across the pharma and medical device industries."Heather is an accomplished leader who brings decades of experience across the pharmaceutical and medical device industries, with a proven track record for

      8/14/24 4:15:00 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation Appoints Richard Fearon to Board of Directors

      Waters™ Corporation (NYSE:WAT) today announced the appointment of Richard Fearon to its Board of Directors, effective March 27, 2023. Mr. Fearon is the former Vice Chairman and Chief Financial and Planning Officer of Eaton Corporation, a multinational power management company. "Rick's expertise is at the intersection of financial excellence, strategic development and transformation, which are the key pillars of Waters' growth plan. We are confident that Rick's unique skillset will complement our Board well and we look forward to benefiting from his insights as we continue to drive value for shareholders," said Dr. Flemming Ornskov, Chairman of the Board. Dr. Udit Batra, CEO and President,

      3/28/23 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Introduces BioResolve Protein A Affinity Columns to Accelerate Antibody Titer Measurement, Enhancing Process Agility and Batch Quality

      News Summary Enables measurements up to 2 days earlier for antibody titers for both clone selection and bioprocess monitoring.1Provides up to 7x improvements in sensitivity with novel high efficiency particles.2Delivers 2x more attribute information with simplified multi-attribute workflows.3MILFORD, Mass., May 28, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced the launch of the BioResolve™ Protein A Affinity Columns with MaxPeak™ Premier Technology, providing precise titer measurements. This launch marks the first set of affinity chromatography columns that Waters has brought to market, in a groundbreaking move as the Company continues to release new products that solve

      5/28/25 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Acquires Halo Labs, Expanding Biological Analysis Portfolio

      MILFORD, Mass., May 21, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) today announced that it has acquired Halo Labs™, an innovator of specialized imaging technologies to detect, identify, and count interfering materials (particles) in therapeutic products, such as cell, protein, and gene therapies. The Aura™ platform from Halo Labs features a highly differentiated technology that performs full spectrum particle analysis and is complementary to the Waters light scattering detection solutions from its Wyatt Technology™ Portfolio. For example, its subvisible particle technology unlocks additional insights when characterizing external particles used to amplify CAR T-cells for cell therapy,

      5/21/25 8:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Waters Corporation to Present at the Jefferies Global Healthcare Conference

      MILFORD, Mass., May 16, 2025 /PRNewswire/ -- Waters Corporation (NYSE:WAT) announced that Udit Batra, Ph.D., Waters President and Chief Executive Officer, will participate in a fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 4th, 2025, at 8:45AM Eastern Time. A live webcast of the event will be available on the 'Events & Presentations' section of Waters Investor Relations website at https://ir.waters.com. A replay of the webcast will be available for 90 days. About Waters Corporation Waters Corporation (NYSE:WAT) is a global leader in analytical instruments, separations technologies, and software, serving the life, materials, food, and environmental sciences f

      5/16/25 11:00:00 AM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $WAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SVP & Chief Financial Officer Chaubal Amol covered exercise/tax liability with 239 shares, decreasing direct ownership by 4% to 5,224 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      5/14/25 5:22:52 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVP TA Instruments Division Bennett Jianqing covered exercise/tax liability with 303 shares, decreasing direct ownership by 6% to 4,916 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/8/25 5:43:17 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Jiang Wei was granted 53 shares, increasing direct ownership by 2% to 2,410 units (SEC Form 4)

      4 - WATERS CORP /DE/ (0001000697) (Issuer)

      4/2/25 5:12:56 PM ET
      $WAT
      Biotechnology: Laboratory Analytical Instruments
      Industrials